Previous 10 | Next 10 |
Alimera Sciences ([[ALIM]] +0.7%) has announced that the three largest private insurers in Ireland representing ~50% of covered lives have approved its eye implant ILUVIEN for reimbursement.The approval applies to NIU-PS (non-infectious uveitis affecting the posterior segment of the...
ATLANTA, March 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces continue...
ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that Pre...
Alimera Sciences, Inc. (ALIM) Q4 2020 Earnings Conference Call February 25, 2021 9:00 AM ET Company Participants Scott Gordon - Core IR Rick Eiswirth - President CEO Phil Jones - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Mr. Chen - H.C. Wainwright James Molloy - Allia...
Image source: The Motley Fool. Alimera Sciences Inc (NASDAQ: ALIM) Q4 2020 Earnings Call Feb 25, 2021 , 9:00 a.m. ET Operator Continue reading For further details see: Alimera Sciences Inc (ALIM) Q4 2020 Earnings Call Transcript
Alimera Sciences (ALIM): Q4 GAAP EPS of -$0.18 misses by $0.16.Revenue of $13.77M (-20.6% Y/Y) beats by $0.77M.Press Release For further details see: Alimera Sciences EPS misses by $0.16, beats on revenue
Fourth Quarter Highlights: Consolidated Net Revenue of $13.8 Million Up 10% vs. Third Quarter of 2020 Consolidated Net Revenue Down 20% vs. Fourth Quarter of 2019 Due to COVID-19 Impact Net Loss of $(1.0) Million vs. Net Income of $0.5 Mil...
ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that ILUVIEN is now available in Finland for diabetic macular ...
ATLANTA, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it wil...
ATLANTA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the M...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Perficient, Inc. (NASDAQ:PRFT)'s sal...
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alimera Sciences, Inc. (NASDAQ:ALIM)'...